PE03152006A1 - Thiazole compounds as PPAR modulators - Google Patents

Thiazole compounds as PPAR modulators

Info

Publication number
PE03152006A1
PE03152006A1 PE0005592005A PE0005592005A PE03152006A1 PE 03152006 A1 PE03152006 A1 PE 03152006A1 PE 0005592005 A PE0005592005 A PE 0005592005A PE 0005592005 A PE0005592005 A PE 0005592005A PE 03152006 A1 PE03152006 A1 PE 03152006A1
Authority
PE
Peru
Prior art keywords
c6
c1
ylmethoxy
r18
xs
Prior art date
Application number
PE0005592005A
Other languages
Spanish (es)
Inventor
Mihai Azimiora
Christopher Cow
Ross Russo
Xing Wang
Yongping Xie
Enrique Saez
Robert Epple
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US57413704P priority Critical
Priority to US64898505P priority
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE03152006A1 publication Critical patent/PE03152006A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/16Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

SE REFIERE A COMPUESTOS DE TIAZOL DE FORMULA (I), EN DONDE p ES DE 0 A 3, L2 ES -XOX-, -XS(O)0-2X Y XS(O)2-2XO-, DONDE X ES INDEPENDIENTEMENTE UN ENLACE Y ALQUILENO(C1-C4); MEANS thiazole compounds of formula (I), wherein p is 0 to 3, L2 ES -xox-, -XS (O) 0-2X Y XS (O) 2-2XO- WHERE X is independently a bond and unsubstituted (C1-C4); R13 ES ALQUILO(C1-C6), ALCOXILO(C1-C6) Y HALOGENO; R13 is (C1-C6) alkoxy (C1-C6) and halogen; R14 ES -XOXC(O)OR17 Y -XC(O)OR17, DONDE X EA ALQUILENO(C1-C4), R17 ES HO ALQUILO(C1-C6); R14 is -XOXC (O) OR 17 and -XC (O) OR 17, wherein X EA (C1-C4), R17 is H or (C1-C6); R15 Y R16 SON INDEPENDIENTEMENTE -R18 E -YR18, EN DONDE Y ES ALQUILENO(C1-C6), ALQUILENO(C2-C6), -C(O)NH, ENTRE OTROS; R15 and R16 -R18 are independently E -YR18, wherein Y is (C1-C6) alkyl, (C2-C6), -C (O) NH, among others; R18 ES ARILO(C6-C10), CICLOALQUILO(C3-C12), Y HETEROARILO(C5-C43) TAL COMO FENILO, BIFENILO, CICLOHEXILO, NAFTILO, BENZO[1,3]DIOXOL-5-ILO, FURANILO, ENTRE OTROS, OPCIONALMENTE SUSTITUIDOS. R18 is aryl (C6-C10), cycloalkyl (C3-C12) heteroaryl (C5-C43) such as phenyl, biphenyl, cyclohexyl, naphthyl, benzo [1,3] dioxol-5-yl, furanyl, IA, optionally substituted. SON PREFERIDOS: ACIDO {4-[4-(4-ISOPROPOXI-FENIL)-5-(4-TRIFLUORO-METOXI-FENIL)-TIAZOL-2-ILMETOXI]-2-METIL-FENOXI}-ACETICO, ACIDO {4-[4-(6-METOXI-PIRIDIN-3-IL)-5-(4-TRIFLUORO-METOXI-FENIL)-TIAZOL-2-ILMETOXI]-2-METIL-FENOXI}-ACETICO, ENTRE OTROS. They are preferred: {4- [4- (4-isopropoxyphenyl) -5- (4-trifluoro-methoxyphenyl) -thiazol-2-ylmethoxy] -2-methyl-phenoxy} acetic acid, {4- [4- (6-Methoxy-pyridin-3-yl) -5- (4-trifluoro-methoxyphenyl) -thiazol-2-ylmethoxy] -2-methyl-phenoxy} -acetic acid, among others. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ADEMAS PUEDE CONTENER OTRO AGENTE ACTIVO TAL COMO ANTIDIABETICOS, HIPOLIPIDEMICOS, REGULADORES DEL APETITO, ENTRE OTROS. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION IN ADDITION MAY CONTAIN OTHER AGENT AS ACTIVE antidiabetic, hypolipidemic, REGULATING APPETITE, among others. ESTOS COMPUESTOS SON MODULADORES DE LA ACTIVIDAD DEL RECPTOR ACTIVADO POR PROLIFERADOR DE PEROXISOMAS ESPECIFICAMENTE DE PPAR*, POR LO QUE SON UTILES EN EL TRATAMIENTO DE DISLIPIDEMIAS, HIPERCOLESTEREMIA, HIPERLIPIDEMIA, INSUFICIENCIA CARDIACA, HIPERTENSION, OBESIDAD Y ENFERMEDADES RELACIONADAS These compounds are modulators ACTIVITY OF THE recptor peroxisome proliferator-activated PPAR SPECIFICALLY *, SO are useful in the treatment of dyslipidemias, hypercholesterolemia, hyperlipidemia, heart failure, hypertension, obesity and RELATED DISEASES
PE0005592005A 2004-05-24 2005-05-20 Thiazole compounds as PPAR modulators PE03152006A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US57413704P true 2004-05-24 2004-05-24
US64898505P true 2005-01-31 2005-01-31

Publications (1)

Publication Number Publication Date
PE03152006A1 true PE03152006A1 (en) 2006-05-15

Family

ID=35450818

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0005592005A PE03152006A1 (en) 2004-05-24 2005-05-20 Thiazole compounds as PPAR modulators

Country Status (16)

Country Link
US (1) US20070203155A1 (en)
EP (1) EP1748993A4 (en)
JP (1) JP2008500355A (en)
AR (1) AR049284A1 (en)
AU (1) AU2005247931B2 (en)
BR (1) BRPI0511477A (en)
CA (1) CA2563818A1 (en)
EC (1) ECSP067021A (en)
IL (1) IL179376D0 (en)
MA (1) MA28660B1 (en)
MX (1) MXPA06013591A (en)
NO (1) NO20065984L (en)
PE (1) PE03152006A1 (en)
RU (1) RU2413723C2 (en)
TW (1) TW200612926A (en)
WO (1) WO2005116000A1 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
US20070015839A1 (en) * 2005-07-14 2007-01-18 Franco Folli Daily Dosage Regimen for Treating Diabetes, Obesity, Metabolic Syndrome and Polycystic Ovary Syndrome
KR101281435B1 (en) 2005-07-26 2013-07-02 글락소 그룹 리미티드 Benzylpiperazine derivatives and their medical use
DE102005035891A1 (en) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8- (3-amino-piperidin-1-yl) -xanthines, their preparation and their use as pharmaceuticals
RU2008122547A (en) * 2005-11-07 2009-12-20 Айрм Ллк (Bm) Compounds and compositions as modulators of arpp (activated receptors of proliferator peroxis)
WO2007056366A2 (en) * 2005-11-07 2007-05-18 Irm Llc Compounds and compositions as ppar modulators
US20090253687A1 (en) * 2005-12-28 2009-10-08 Shoji Fukumoto Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands
PE02512008A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Uses DPP IV inhibitors
CN103951667A (en) 2006-05-04 2014-07-30 勃林格殷格翰国际有限公司 Polymorphs
WO2008083124A1 (en) 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
BRPI0807552A2 (en) * 2007-02-22 2014-07-01 Irm Llc Compounds and methods for modulating g-protein-coupled receptors
ES2552733T3 (en) 2007-11-16 2015-12-01 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
US8129390B2 (en) 2007-12-12 2012-03-06 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using the same
CA2718936A1 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
AU2012203026B2 (en) * 2008-03-21 2014-06-12 Novartis Ag Novel heterocyclic compounds and uses thereof
PE09602014A1 (en) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulations comprising a DPP4 inhibitor
ES2552549T3 (en) 2008-04-23 2015-11-30 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
KR20190016601A (en) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 Treatment for diabetes in patients inappropriate for metformin therapy
UY32030A (en) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "Treatment for diabetes in patients unsuitable for therapy with metformin"
MX2011002558A (en) 2008-09-10 2011-04-26 Boehringer Ingelheim Int Combination therapy for the treatment of diabetes and related conditions.
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
CA2797310A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
KR20190050871A (en) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8962636B2 (en) 2011-07-15 2015-02-24 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6224084B2 (en) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Xanthine derivatives as DPP-4 inhibitors for the treatment of glomerular epithelial cell related disorders and / or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag Compounds and compositions as kinase inhibitors
US20180008616A1 (en) * 2015-02-06 2018-01-11 Intercept Pharmaceuticals, Inc. Pharmaceutical compositions for combination therapy
WO2017095723A1 (en) * 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
CN109310697A (en) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 The combination of Li Gelieting and melbine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR74148B (en) * 1980-04-03 1984-06-06 Wyeth John & Brother Ltd
IT1248528B (en) * 1991-06-21 1995-01-19 Pierrel Spa Derivatives of ethers and thioethers (hetero) aromatics having antiiperlipidemica activities, process for their preparation and pharmaceutical compositions containing them.
JP3197602B2 (en) * 1992-02-17 2001-08-13 久光製薬株式会社 Thiazole analogous compounds and skin external preparation
JPH11147881A (en) * 1997-08-21 1999-06-02 Sankyo Co Ltd Herbicidal azole derivative having dihydrobenzoquinone skeleton
AT451346T (en) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carboxylene derivatives and medicaments containing these as active active substances
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US20030170858A1 (en) * 2001-01-16 2003-09-11 Paul Charifson Gyrase inhibitors and uses thereof
AU7772301A (en) * 2000-08-11 2002-02-25 Nippon Chemiphar Co Ppardelta activators
JP2002348281A (en) * 2001-03-23 2002-12-04 Takeda Chem Ind Ltd Five-membered heterocyclic alkane acid derivative
EP1371650A4 (en) * 2001-03-23 2005-05-04 Nippon Chemiphar Co Activator for peroxisome proliferator-activated receptor
EP2314576A1 (en) * 2003-11-05 2011-04-27 F.Hoffmann-La Roche Ag Phenyl derivatives as PPAR agonists

Also Published As

Publication number Publication date
AU2005247931B2 (en) 2008-10-23
IL179376D0 (en) 2007-03-08
ECSP067021A (en) 2006-12-29
TW200612926A (en) 2006-05-01
BRPI0511477A (en) 2007-12-26
JP2008500355A (en) 2008-01-10
EP1748993A4 (en) 2010-04-28
US20070203155A1 (en) 2007-08-30
NO20065984L (en) 2007-02-05
CA2563818A1 (en) 2005-12-08
RU2413723C2 (en) 2011-03-10
WO2005116000A1 (en) 2005-12-08
MXPA06013591A (en) 2007-03-15
EP1748993A1 (en) 2007-02-07
AR049284A1 (en) 2006-07-12
MA28660B1 (en) 2007-06-01
RU2006145894A (en) 2008-06-27
AU2005247931A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
ES2461615T3 (en) Apoptosis promoters containing N-acylsulfonamide
JP5140577B2 (en) Hydroxysteroid dehydrogenase inhibitor
RU2412192C2 (en) Sulphonamidethiazole pyridine derivatives as glucokinase activators, suitable for treating type-2 diabetes
US7495018B2 (en) Substituted 1,3-thiazole compounds, their production and use
US7687504B2 (en) Pyrrolidine compounds
US7683094B2 (en) 8-azaprostaglandin derivative compound and agent comprising the compound as active ingredient
ES2249919T3 (en) Inhibitors of the biosopesis of prostaglandina endoperoxido h sintasa.
EP1487829B1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
US9242977B2 (en) Trk-inhibiting compound
JP2008524244A (en) Hydroxyl steroid dehydrogenase inhibitor
DE602004011511T2 (en) N - ((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulphonyl) phenylalanine derivatives and related compounds for the treatment of diabetes
RU2324684C2 (en) Pyrimidine derivatives
DK2038265T3 (en) Inhibitors of human protein tyrosine phosphatase and methods of use
KR101081293B1 (en) Thiazoles as 11 beta-hsd1 inhibitors
US6576630B1 (en) Compounds and compositions as protease inhibitors
US20040044003A1 (en) Therapeutic agents useful for treating pain
EP1482924A4 (en) Cathepsin cysteine protease inhibitors
WO2003048109A1 (en) Novel glucagon antagonists
CZ20011864A3 (en) Compounds of substituted indole alkanoic acids and their use for increasing serum concentrations of triglycerides
PE57799A1 (en) Arilsulfonilaminohidroxamicos acid derivatives
JPH10504542A (en) Substituted thiazole compounds for inflammation treatment
KR20040043197A (en) Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments
NZ526715A (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
IS8395A (en) Fjölvasýklískar carboxylic acids and asýlsúlfónamíð potent inhibitor of hepatitis C replication
PE06112009A1 (en) Process for synthesizing compounds for treating hepatitis useful c

Legal Events

Date Code Title Description
FC Refusal